microRNA-26a-5p affects myocardial injury induced by coronary microembolization by modulating HMGA1

Area of Science:

• Cardiovascular Biology
• Molecular Medicine
• Biomedical Research

Background:

• Coronary microembolization (CME) during Percutaneous Coronary Intervention (PCI) for acute coronary syndrome leads to myocardial damage and inflammation.
• MicroRNAs (miRNAs) are implicated in cardiovascular diseases, with miR-26a-5p linked to various cardiac conditions.
• The specific role of miR-26a-5p in CME-induced myocardial injury remains largely unexplored.

Purpose of the Study:

• To investigate the role of miR-26a-5p in myocardial injury following coronary microembolization (CME).
• To determine if miR-26a-5p overexpression can mitigate CME-induced cardiac dysfunction and inflammation.
• To identify HMGA1 as a potential target gene of miR-26a-5p in this context.

Main Methods:

• Establishment of a rat model of CME via left ventricular injection of microembolic balls.
• Assessment of cardiac function using echocardiography and myocardial inflammation via hematoxylin-eosin staining.
• Analysis of miR-26a-5p expression and protein levels using real-time PCR and Western blot.
• In vitro studies including dual luciferase reporter assays to confirm gene targets.

Main Results:

• CME induction led to decreased miR-26a-5p expression in rat myocardial tissue.
• Overexpression of miR-26a-5p significantly alleviated CME-induced cardiac dysfunction and myocardial inflammation.
• Inhibition of miR-26a-5p exacerbated CME-induced myocardial injury.
• HMGA1 was identified as a direct target gene of miR-26a-5p.

Conclusions:

• miR-26a-5p plays a protective role against CME-induced myocardial damage.
• Overexpression of miR-26a-5p ameliorates cardiac dysfunction and inflammation post-CME, potentially by downregulating HMGA1.
• miR-26a-5p represents a promising therapeutic target for managing myocardial injury resulting from coronary microembolization.